A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Recruiting now · Phase 1

Conditions studied: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

In brief

This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.

Key facts

Study ID

NCT05885412

Run by

Rocket Pharmaceuticals Inc.

People needed

9

Starts

2023-08-29

Expected to finish

2029-09-01

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California, San Diego — La Jolla, California, United States (enrolling)
• Duke University — Durham, North Carolina, United States (enrolling)
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.